Abstract
β-Secretase is an attractive target of amyloid-reduction therapy for Alzheimer's disease. Currently, no efficacy data is available from clinical trials of β-secretase inhibitors. Treating young transgenic Tg2576 mice with a brain-penetrating β-secretase inhibitor reduced brain amyloid-β by about 50% and rescued the age-related cognitive decline. Implications from these model studies on the design of clinical trials are discussed herein.
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / pathology
-
Alzheimer Disease / physiopathology
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid beta-Protein Precursor / metabolism
-
Animals
-
Clinical Trials as Topic
-
Enzyme Inhibitors / therapeutic use*
-
Humans
-
Mice
-
Mice, Transgenic*
Substances
-
APP protein, human
-
Amyloid beta-Protein Precursor
-
Enzyme Inhibitors
-
Amyloid Precursor Protein Secretases